| scholarly article | Q13442814 |
| P2093 | author name string | Hatem A Azim | |
| Hamdy A Azim | |||
| P2860 | cites work | Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer | Q24621947 |
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models | Q28473716 | ||
| The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter | Q28477938 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Targeting multidrug resistance in cancer | Q29616803 | ||
| Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain | Q33283845 | ||
| Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. | Q33386298 | ||
| The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline | Q33599111 | ||
| Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience. | Q33747400 | ||
| Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. | Q33878643 | ||
| Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab | Q48612753 | ||
| Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases | Q49123747 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. | Q54573427 | ||
| Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. | Q54654985 | ||
| Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System | Q57407206 | ||
| Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials | Q33939795 | ||
| Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death | Q34022312 | ||
| Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). | Q34341349 | ||
| Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer | Q34393640 | ||
| Breast cancer metastasis to the central nervous system | Q34455205 | ||
| The blood-brain barrier and cancer: transporters, treatment, and Trojan horses | Q34577796 | ||
| Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review | Q34583604 | ||
| Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm | Q34632917 | ||
| Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. | Q34779629 | ||
| Regulation and function of cyclic nucleotides | Q35256720 | ||
| Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up | Q35720625 | ||
| Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer | Q35914677 | ||
| Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development | Q36874299 | ||
| Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain | Q36954809 | ||
| A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses | Q37054957 | ||
| PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model | Q37076589 | ||
| Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 | Q37119716 | ||
| LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies | Q37216064 | ||
| Targeting Her-2/neu in breast cancer: as easy as this! | Q37245691 | ||
| Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain | Q37278215 | ||
| International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy | Q37329165 | ||
| Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases | Q37601140 | ||
| Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier | Q37819809 | ||
| Metastatic behavior of breast cancer subtypes | Q38416421 | ||
| Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines | Q39799826 | ||
| The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma | Q40490061 | ||
| Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer | Q42463524 | ||
| Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). | Q43846885 | ||
| Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer | Q44176007 | ||
| Preliminary results of whole brain radiotherapy with concurrent trastuzumab for treatment of brain metastases in breast cancer patients | Q44689634 | ||
| A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen | Q45125373 | ||
| Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer | Q46116627 | ||
| Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. | Q46362575 | ||
| Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer | Q46606673 | ||
| Capecitabine therapy of central nervous system metastases from breast cancer | Q48115520 | ||
| Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer | Q48142933 | ||
| Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival | Q48253215 | ||
| CXCR4 expression in early breast cancer and risk of distant recurrence | Q48398507 | ||
| Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer | Q48575675 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain metastasis | Q1620196 |
| P304 | page(s) | 135-144 | |
| P577 | publication date | 2012-02-01 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions | |
| P478 | volume | 8 |
| Q59339787 | A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases |
| Q36288549 | Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes |
| Q89257523 | Antibody pharmacokinetics in rat brain determined using microdialysis |
| Q47606935 | Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology |
| Q38846435 | Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer |
| Q37136423 | Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study |
| Q48268775 | HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report |
| Q44134898 | Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial |
| Q46014242 | Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain. |
| Q34686390 | Surgical resection of brain metastases-impact on neurological outcome |
| Q36746835 | Synergistic Effect between Sphingosine-1-Phosphate and Chemotherapy Drugs against Human Brain-metastasized Breast Cancer MDA-MB-361 cells |
Search more.